scholarly journals Establishment of new predictive markers for distant recurrence of colorectal cancer using lectin microarray analysis

2014 ◽  
Vol 4 (2) ◽  
pp. 293-302 ◽  
Author(s):  
Kentaro Nakajima ◽  
Masafumi Inomata ◽  
Hidekatsu Iha ◽  
Takahiro Hiratsuka ◽  
Tsuyoshi Etoh ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Microarray Analysis ◽  
Distant Recurrence ◽  
Predictive Markers ◽  
Lectin Microarray

scholarly journals Correction: Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer

2019 ◽  
Vol 121 (11) ◽  
pp. 983-984 ◽  
Author(s):  
Taichi Kuwahara ◽  
Shoichi Hazama ◽  
Nobuaki Suzuki ◽  
Shin Yoshida ◽  
Shinobu Tomochika ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
T Cells ◽  
Predictive Markers

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Tumor Budding and Pathological Differentiation Are Predictive Markers for Lymph Node Metastasis in T1 Colorectal Cancer

2006 ◽  
Vol 63 (5) ◽  
pp. AB216 ◽  
Author(s):  
Hitoshi Yamauchi ◽  
Kazutomo Togashi ◽  
Hiroshi Kawamura ◽  
Junichi Sasaki ◽  
Masaki Okada ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Predictive Markers ◽  
Tumor Budding ◽  
Node Metastasis ◽  
Pathological Differentiation ◽  
T1 Colorectal Cancer

scholarly journals Role ofNRASmutations as prognostic and predictive markers in metastatic colorectal cancer

2014 ◽  
Vol 136 (1) ◽  
pp. 83-90 ◽  
Author(s):  
Marta Schirripa ◽  
Chiara Cremolini ◽  
Fotios Loupakis ◽  
Manfredi Morvillo ◽  
Francesca Bergamo ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Predictive Markers ◽  
Prognostic And Predictive Markers

scholarly journals Exploration of the mechanism of colorectal cancer metastasis using microarray analysis

2017 ◽  
Author(s):  
Shuo Chen ◽  
Yan Wang ◽  
Lin Zhang ◽  
Yinan Su ◽  
Mingqing Zhang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Microarray Analysis ◽  
Cancer Metastasis ◽  
Colorectal Cancer Metastasis

scholarly journals Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score

2015 ◽  
Vol 33 (8) ◽  
pp. 916-922 ◽  
Author(s):  
Ivana Sestak ◽  
Jack Cuzick ◽  
Mitch Dowsett ◽  
Elena Lopez-Knowles ◽  
Martin Filipits ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Value ◽  
Randomized Trials ◽  
Distant Recurrence ◽  
Study Group ◽  
Combined Analysis ◽  
Risk Of Recurrence ◽  
Cancer Study ◽  
Cancer Study Group

Purpose We have previously shown that the PAM50-based risk of recurrence (ROR) score is significantly correlated with distant recurrence in both the translational research cohort within the Arimidex, Tamoxifen Alone or in Combination (ATAC) trial (TransATAC) and Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG 8) randomized trials. Here, we focus on the ROR score for predicting distant recurrence after 5 years of follow-up in a combined analysis of these two randomized trials. Methods Long-term follow-up data and tissue samples were obtained from 2,137 postmenopausal women with hormone receptor–positive early-stage breast cancer from the ABCSG 8 and TransATAC trials. We used Cox proportional hazard regression models to determine the prognostic value of ROR for distant recurrence beyond 5 years in the combined data set. Results A total of 2,137 women who did not have a recurrence 5 years after diagnosis were included in the combined analyses. The Clinical Treatment Score (CTS) was the strongest prognostic factor 5 years after diagnosis (univariable: likelihood ratio [LR] χ2 = 94.12, bivariable: LR χ2 = 61.43). The ROR score was significantly prognostic by itself in years 5 to 10. In the node-negative/human epidermal growth factor receptor 2–negative subgroup, more prognostic value for late distant recurrence was added by the ROR score compared with the CTS. Conclusion The ROR score added clinically meaningful prognostic information to the CTS in all patients and all subgroups in the late follow-up period. These results suggest that the ROR score may be helpful for separating patients into risk groups who could be spared or potentially benefit from extended hormonal therapy beyond 5 years of treatment.

Sign in / Sign up

Export Citation Format

Share Document